13G Filing: Armistice Capital and Eyegate Pharmaceuticals Inc (EYEG)

Page 5 of 10

Page 5 of 10 – SEC Filing

CUSIP No
30233M107
Item 1.
(a).
Name of Issuer:
Eyegate Pharmaceuticals, Inc.
(b).
Address of Issuer’s Principal Executive Offices:
271 Waverley Oaks Road, Suite 108
Waltham, Massachusetts  02452
United States of America
Item 2.
(a).
Name of Person Filing:
Armistice Capital, LLC
Armistice Capital Master Fund Ltd.
Steven Boyd
(b).
Address of Principal Business Office, or if None, Residence:
Armistice Capital, LLC
510 Madison Avenue, 22nd Floor
New York, New York 10022
United States of America
Armistice Capital Master Fund Ltd.
c/o dms Corporate Services Ltd.
20 Genesis Close
P.O. Box 314
Grand Cayman KY1-1104
Cayman Islands
Steven Boyd
c/o Armistice Capital, LLC
510 Madison Avenue, 22nd Floor
New York, New York 10022
United States of America
(c)
Citizenship:
Armistice Capital, LLC – Delaware
Armistice Capital Master Fund Ltd. – Cayman Islands
Steven Boyd – United States of America
(d).
Title of Class of Securities:
Common Stock, $0.01 par value per share
(e).
CUSIP Number:
30233M107

Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)

Page 5 of 10